Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

BioXcel Could Make ‘Unique Play’ In Neurology, Oncology, Barclays Says In Bullish Initiation

Courtesy of Benzinga.

BioXcel Could Make 'Unique Play' In Neurology, Oncology, Barclays Says In Bullish Initiation

Strong clinical data from BioXcel Therapeutics Inc (NASDAQ: BTAI)’s two key assets could give the early stage biopharma company a unique play in the neurology and oncology fields, according to Barclays. 

The Analyst

Analyst Geoff Meacham initiated coverage on BioXcel with an Overweight rating and $15 price target.

The Thesis

BioXcel’s BXL105 is in development for acute agitation associated with Alzheimer’s, schizophrenia and bipolar disorder.

So far, clinical data has suggested better safety and efficacy results than other agents, Meacham said in a Monday note. 

“While there is more clinical data needed to fully de-risk the asset, we are comfortable with the probability of success and ultimately, we forecast peak sales in the $700 million range.” 

Meacham describes BXCL701, the company’s second key asset, as a “novel oncology drug in development for treatment-emergent neuroendocrine tumors in prostate cancer and pancreatic cancer.” 

The drug could reach peak sales in the $700-million range given the unmet need in both tNPEC and pancreatic cancer, the analyst said.

“Given what we view a unique play in both neurology and oncology as well as AI, with clinical data expected over the next 12 months, we see good upside potential for BTAI shares.” 

Price Action

BioXcel shares were trading up 5.46 percent at the time of publication Monday. 

Related Links: 

Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease

The Companies That Led 2017′s Biotech Rally

Latest Ratings for BTAI

Date Firm Action From To
Apr 2018 UBS Initiates Coverage On Buy
Apr 2018 BMO Capital Initiates Coverage On Outperform
Apr 2018 Canaccord Genuity Initiates Coverage On Buy

View More Analyst Ratings for BTAI


View the Latest Analyst Ratings

Posted-In: Barclays Geoff MeachamAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!